To evaluate the efficacy of intravitreal triamcinolone acetonide injection on persistent macular oedema in branch retinal vein occlusion that fails to respond to previous laser photocoagulation. The ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

We show that intravitreal Bevacizumab treatment for macular edema induced by BRVO leads to a fast and significant improvement of visual acuity and a concurrent decrease of CRT. Similar results were ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

Scientists have found that laser therapy is equivalent to two different dosages of corticosteroid medications for treating vision loss from the blockage of small veins in the back of the eye, a ...

– If approved by the FDA, RVO would be Vabysmo’s third indication in addition to wet age-related macular degeneration (AMD) and diabetic macular edema (DME) – – Vabysmo is the first and only treatment ...

Leuven, April 23, 2015 - ThromboGenics NV (Euronext Brussels:THR), an integrated biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of ...

Treatment with high dose aflibercept 8 mg can lead to similar visual outcomes with fewer injections for patients with RVO.

Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...